25.59
+0.02(+0.08%)
Currency In USD
Address
200 Smith Street
Waltham, MA 02451
United States of America
Phone
781 209 6400
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
355
First IPO Date
September 28, 2017
| Name | Title | Pay | Year Born |
| Steven L. Hoerter | President, Chief Executive Officer & Director | 1.24M | 1971 |
| Dashyant Dhanak | Executive Vice President & Chief Scientific Officer | 498,455 | 1963 |
| Daniel C. Martin | Senior Vice President & Chief Commercial Officer | 727,534 | 1975 |
| Thomas Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer | 772,473 | 1971 |
| Matthew L. Sherman | Executive Vice President & Chief Medical Officer | 870,583 | 1956 |
| Kevin Brodbeck | Senior Vice President & Chief Technical Officer | 0 | N/A |
| Rodrigo Ruiz Soto | Senior Vice President of Clinical Development | 0 | N/A |
| Jennifer Larson | Senior Vice President of Finance & Investor Relations | 0 | N/A |
| Madhumita Bogdan | Senior Principal Investigator of Biological Sciences | 0 | N/A |
| Jeffrey Held | Senior Vice President & General Counsel | 0 | N/A |
| Jama Pitman | Senior Vice President & Chief Development Officer | 0 | 1979 |
| Jennifer Robinson | Vice President of Investor Relations | 0 | N/A |
| Kelley Dealhoy | Senior Vice President & Chief Business Officer | 0 | N/A |
| Lisa Amaya Price | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
| Margarida Duarte | Senior Vice President & Head of International | 0 | N/A |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.